Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 347


Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer.

Schiff JP, Cotogno P, Feibus A, Steinwald P, Ledet E, Lewis B, Sartor O.

BMC Cancer. 2019 May 31;19(1):524. doi: 10.1186/s12885-019-5729-7.


The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer.

Dorff TB, Fanti S, Farolfi A, Reiter RE, Sadun TY, Sartor O.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:321-330. doi: 10.1200/EDBK_239187. Epub 2019 May 17.


Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.

Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM.

J Clin Oncol. 2019 May 10;37(14):1159-1168. doi: 10.1200/JCO.18.02158. Epub 2019 Mar 12.


Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.

Chen B, Nagai S, Armitage JO, Witherspoon B, Nabhan C, Godwin AC, Yang YT, Kommalapati A, Tella SH, DeAngelis C, Raisch DW, Sartor O, Hrushesky WJ, Ray PS, Yarnold PR, Love BL, Norris LB, Knopf K, Bobolts L, Riente J, Luminari S, Kane RC, Hoque S, Bennett CL.

Oncologist. 2019 Apr;24(4):537-548. doi: 10.1634/theoncologist.2018-0341. Epub 2019 Mar 6.


Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.

Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, O'Leary E, Esplin ED, Nussbaum RL, Sartor O.

JAMA Oncol. 2019 Feb 7. doi: 10.1001/jamaoncol.2018.6760. [Epub ahead of print]


Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.

Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB.

Cancer. 2019 May 1;125(9):1459-1469. doi: 10.1002/cncr.31959. Epub 2019 Jan 8.


Androgen deprivation therapy in prostate cancer: new findings and questions for the future.

Sartor O.

Lancet Oncol. 2019 Feb;20(2):176-177. doi: 10.1016/S1470-2045(18)30893-3. Epub 2018 Dec 19. No abstract available.


Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs.

Layton JL, Lewis B, Ryan C, Beer TM, Sartor O.

Oncologist. 2019 Mar;24(3):291-292. doi: 10.1634/theoncologist.2018-0565. Epub 2018 Dec 19. No abstract available.


Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer.

Manogue C, Cotogno P, Ledet E, Lewis B, Wyatt AW, Sartor O.

Oncologist. 2019 Apr;24(4):444-448. doi: 10.1634/theoncologist.2018-0546. Epub 2018 Dec 12.


Synergistic Interactions: Targeted Radiopharmaceuticals and Homologous Recombination Repair Alterations in Prostate Cancer.

Sartor O.

Eur Urol. 2018 Dec 1. pii: S0302-2838(18)30940-0. doi: 10.1016/j.eururo.2018.11.041. [Epub ahead of print] No abstract available.


Advanced prostate cancer update 2018.

Sartor O.

Asia Pac J Clin Oncol. 2018 Nov;14 Suppl 5:9-12. doi: 10.1111/ajco.13057. Review.


Conflicts of Interest, Baselga, and Clinical Trialists.

Sartor O.

Oncologist. 2018 Dec;23(12):1394. doi: 10.1634/theoncologist.2018-0663. Epub 2018 Oct 24. No abstract available.


Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer.

Cheng H, Powers J, Schaffer K, Sartor O.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:372-381. doi: 10.1200/EDBK_205441. Review.


Radium and other alpha emitters in prostate cancer.

Sartor O, Sharma D.

Transl Androl Urol. 2018 Jun;7(3):436-444. doi: 10.21037/tau.2018.02.07. Review.


Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker.

Heinrich D, Bruland Ø, Guise TA, Suzuki H, Sartor O.

Future Oncol. 2018 Oct;14(24):2543-2556. doi: 10.2217/fon-2018-0087. Epub 2018 Jun 21. Review.


Association Between Androgen Deprivation Therapy and Patient-reported Depression in Men With Recurrent Prostate Cancer.

Thomas HR, Chen MH, D'Amico AV, Bennett CL, Kattan MW, Sartor O, Stein K, Nguyen PL.

Clin Genitourin Cancer. 2018 Aug;16(4):313-317. doi: 10.1016/j.clgc.2018.05.007. Epub 2018 Jun 1.


Editorial Comment.

Qureshi ZP, Sartor O, Ablin RJ, Bennett CL.

Urology. 2018 Aug;118:125-126. doi: 10.1016/j.urology.2018.02.050. Epub 2018 May 28. No abstract available.


Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.

Miyahira AK, Pienta KJ, Morris MJ, Bander NH, Baum RP, Fendler WP, Goeckeler W, Gorin MA, Hennekes H, Pomper MG, Sartor O, Tagawa ST, Williams S, Soule HR.

Prostate. 2018 Aug;78(11):775-789. doi: 10.1002/pros.23642. Epub 2018 May 1. Review.


Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer.

Cotogno PM, Ranasinghe LK, Ledet EM, Lewis BE, Sartor O.

Oncologist. 2018 Jul;23(7):791-797. doi: 10.1634/theoncologist.2017-0564. Epub 2018 Apr 26.


Metastatic Prostate Cancer.

Sartor O, de Bono JS.

N Engl J Med. 2018 Apr 26;378(17):1653-1654. doi: 10.1056/NEJMc1803343. No abstract available.


Curing More Prostate Cancer: Thinking Through the Options.

Sartor O.

J Clin Oncol. 2018 May 20;36(15):1466-1468. doi: 10.1200/JCO.2018.78.4835. Epub 2018 Apr 6. No abstract available.


Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).

Mehra N, Dolling D, Sumanasuriya S, Christova R, Pope L, Carreira S, Seed G, Yuan W, Goodall J, Hall E, Flohr P, Boysen G, Bianchini D, Sartor O, Eisenberger MA, Fizazi K, Oudard S, Chadjaa M, Macé S, de Bono JS.

Eur Urol. 2018 Sep;74(3):283-291. doi: 10.1016/j.eururo.2018.02.013. Epub 2018 Feb 28.


First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy.

Valicenti RK, Pugh SL, Trabulsi EJ, Sartor O, Ko EC, Girvigian MR, Rosenthal SA, Shaves ME, Hoffman-Censits JH, Schallenkamp J, Sandler HM.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):695-701. doi: 10.1016/j.ijrobp.2017.11.024. Epub 2017 Nov 21.


Metastatic Prostate Cancer.

Sartor O, de Bono JS.

N Engl J Med. 2018 Feb 15;378(7):645-657. doi: 10.1056/NEJMra1701695. Epub 2018 Feb 7. Review. No abstract available.


Editorial Comment.

Qureshi ZP, Sartor O, Bennett CL.

Urology. 2018 Mar;113:144-145. doi: 10.1016/j.urology.2017.08.068. Epub 2017 Dec 27. No abstract available.


Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer.

Manogue C, Ledet E, Guddati AK, Lewis B, Sartor O.

Oncologist. 2018 Mar;23(3):383-385. doi: 10.1634/theoncologist.2017-0450. Epub 2017 Dec 19.


Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13.


Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.

Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A Jr, Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ; U.S. Expanded Access Program Investigators.

Oncologist. 2018 Feb;23(2):193-202. doi: 10.1634/theoncologist.2017-0413. Epub 2017 Nov 28.


Adverse Event Reporting in Clinical Trials: Time to Include Duration as Well as Severity.

Sartor O.

Oncologist. 2018 Jan;23(1):1. doi: 10.1634/theoncologist.2017-0437. Epub 2017 Nov 20. No abstract available.


Understanding the distressed prostate cancer patient: Role of personality.

Perry LM, Hoerger M, Silberstein J, Sartor O, Duberstein P.

Psychooncology. 2018 Mar;27(3):810-816. doi: 10.1002/pon.4579. Epub 2017 Dec 7.


A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer.

Seyednasrollah F, Koestler DC, Wang T, Piccolo SR, Vega R, Greiner R, Fuchs C, Gofer E, Kumar L, Wolfinger RD, Kanigel Winner K, Bare C, Neto EC, Yu T, Shen L, Abdallah K, Norman T, Stolovitzky G, Soule HR, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Elo LL, Zhou FL, Guinney J, Costello JC; Prostate Cancer DREAM Challenge Community.

JCO Clin Cancer Inform. 2017 Nov;1:1-15. doi: 10.1200/CCI.17.00018.


Abiraterone in Metastatic Prostate Cancer.

de Bono J, Eisenberger M, Sartor O.

N Engl J Med. 2017 Oct 26;377(17):1694-5. doi: 10.1056/NEJMc1711029. No abstract available.


Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.

Sartor O, Heinrich D, Mariados N, Méndez Vidal MJ, Keizman D, Thellenberg Karlsson C, Peer A, Procopio G, Frank SJ, Pulkkanen K, Rosenbaum E, Severi S, Trigo Perez JM, Wagner V, Li R, Nordquist LT.

Ann Oncol. 2017 Oct 1;28(10):2464-2471. doi: 10.1093/annonc/mdx331.


Editorial Comment.

Qureshi ZP, Sartor O, Bennett CL.

Urology. 2017 Nov;109:16-17. doi: 10.1016/j.urology.2017.04.063. Epub 2017 Sep 21. No abstract available.


Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer.

Pezaro CJ, Omlin A, Mastris K; ANZUP Consumer Advisory Panel, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS, Hussain M, James N, Logothetis CJ, Morgans A, Parker C, Ryan CJ, Saad F, Sartor O, Small EJ, Sternberg CN, Sweeney CJ, Tannock I, Tombal B, Gillessen S.

Ann Oncol. 2017 Aug 1;28(8):1692-1694. doi: 10.1093/annonc/mdx312. No abstract available.


Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.

Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Clarke NW, Collette L, Dignam JJ, Fizazi K, Paruleker WR, Sandler HM, Sydes MR, Tombal B, Williams SG, Sweeney CJ; ICECaP Working Group.

J Clin Oncol. 2017 Sep 20;35(27):3097-3104. doi: 10.1200/JCO.2017.73.9987. Epub 2017 Aug 10.


Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.

Oudard S, Fizazi K, Sengeløv L, Daugaard G, Saad F, Hansen S, Hjälm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, Castellano D, Mainwaring PN, Bernard J, Shen L, Chadjaa M, Sartor O.

J Clin Oncol. 2017 Oct 1;35(28):3189-3197. doi: 10.1200/JCO.2016.72.1068. Epub 2017 Jul 28.


Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Bruland ØS, Petrenciuc O, Staudacher K, Li R, Nilsson S.

Eur Urol. 2017 Jul 10. pii: S0302-2838(17)30516-X. doi: 10.1016/j.eururo.2017.06.021. [Epub ahead of print]


Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A.

Eur Urol. 2018 Feb;73(2):178-211. doi: 10.1016/j.eururo.2017.06.002. Epub 2017 Jun 24.


Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR).

Sabol RA, Noxon V, Sartor O, Berger JR, Qureshi Z, Raisch DW, Norris LB, Yarnold PR, Georgantopoulos P, Hrushesky WJ, Bobolts L, Ray P, Lebby A, Kane RC, Bennett CL.

Cancer Med. 2017 Jul;6(7):1541-1551. doi: 10.1002/cam4.1098. Epub 2017 Jun 20. Review.


Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature.

Summers N, Vanderpuye-Orgle J, Reinhart M, Gallagher M, Sartor O.

Curr Med Res Opin. 2017 Nov;33(11):1995-2008. doi: 10.1080/03007995.2017.1341869. Epub 2017 Jul 10. Review.


An Integrative Genomics Approach for Associating Genome-Wide Association Studies Information With Localized and Metastatic Prostate Cancer Phenotypes.

Hicks C, Ramani R, Sartor O, Bhalla R, Miele L, Dlamini Z, Gumede N.

Biomark Insights. 2017 Mar 16;12:1177271917695810. doi: 10.1177/1177271917695810. eCollection 2017.


An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.

Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Vogelzang NJ, Bruland Ø, Kobina S, Wilhelm S, Xu L, Shan M, Kattan MW, Parker C.

Ann Oncol. 2017 May 1;28(5):1090-1097. doi: 10.1093/annonc/mdx044.


Advantages of a Truly Open-Access Data-Sharing Model.

Bertagnolli MM, Sartor O, Chabner BA, Rothenberg ML, Khozin S, Hugh-Jones C, Reese DM, Murphy MJ.

N Engl J Med. 2017 Mar 23;376(12):1178-1181. doi: 10.1056/NEJMsb1702054. No abstract available.


Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.

Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CAF, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM.

Cancer. 2017 Jul 1;123(13):2489-2496. doi: 10.1002/cncr.30620. Epub 2017 Mar 21.


Navigating the evolving therapeutic landscape in advanced prostate cancer.

Crawford ED, Petrylak D, Sartor O.

Urol Oncol. 2017 May;35S:S1-S13. doi: 10.1016/j.urolonc.2017.01.020. Epub 2017 Mar 7. Review.


Editorial Comment.

Sartor O.

Urology. 2017 Apr;102:171-172. doi: 10.1016/j.urology.2016.10.045. Epub 2017 Mar 6. No abstract available.


Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, Kattan MW, Lin DW.

CA Cancer J Clin. 2017 May 6;67(3):245-253. doi: 10.3322/caac.21391. Epub 2017 Feb 21.


Generic drugs in oncology - Authors' reply.

Bennett CL, Nagai S, Yang YT, Chen BK, Sartor O, Armitage JO.

Lancet Oncol. 2017 Feb;18(2):e64. doi: 10.1016/S1470-2045(17)30016-5. No abstract available.


Supplemental Content

Loading ...
Support Center